Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Maodongqing is a combination medication used in Traditional Chinese Medicine (TCM) for the treatment of the common cold, influenza, and associated symptoms such as fever, headache, and sore throat. The formulation typically integrates herbal extracts with Western pharmacological agents to provide a multi-targeted therapeutic effect. The primary herbal component is derived from *Ilex pubescens* (Maodongqing), which is traditionally valued for its heat-clearing, detoxifying, and anti-inflammatory properties. To enhance its efficacy against acute cold symptoms, the compound often includes paracetamol (acetaminophen) for its antipyretic and analgesic actions, and chlorpheniramine maleate, an antihistamine that relieves nasal congestion, sneezing, and rhinorrhea. Some formulations may also incorporate *Evodia lepta* (Sanchaku) for additional anti-inflammatory and analgesic support. It is commonly developed and manufactured by regional pharmaceutical companies in China, such as Shangqiu Zhongsen Pharmaceutical Technology, for over-the-counter use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compound Maodongqing.